Tirzepatide
GIP + GLP-1
A dual-action incretin compound with some of the strongest average weight-loss data in current use.
How It Works
Tirzepatide activates both GIP and GLP-1 pathways, combining appetite suppression with broader metabolic effects.
Practical Information
injection
Tirzepatide is discussed as a weekly injectable incretin, with practical attention on titration, GI tolerance, and stronger average weight-loss expectations than older GLP-1 options.
2.5mg weekly at the start, titrated upward over time to as much as 15mg weekly.
Products
Verified sources. Not ranked.
Related Articles
See all 3 articles →Retatrutide vs Tirzepatide: Bigger Promise, or Better Right Now?
Tirzepatide is the settled, approved option you can start using today. Retatrutide shows bigger weight-loss potential but remains investigational. Your pick depends on whether you want certainty now or the highest ceiling later.
4 min read
Tirzepatide Weight Loss: Why the Appetite Shift Feels So Different
Tirzepatide shifted weight-loss expectations because the appetite change feels genuinely different—quieter, more automatic—and the results back it up. The real decision is whether the weekly routine, the side-effect ramp, and current 2026 pricing work for your life.
4 min read